HC Wainwright & Co. Upgrades KemPharm to Buy, Raises Price Target to $11
HC Wainwright & Co. analyst Oren Livnat upgrades KemPharm (NASDAQ:KMPH) from Neutral to Buy and raises the price target from $10 to $11.
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline.
KemPharm CEO Sends Shareholder Letter, Highlights Strategic Focus
KemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate
Strong Balance Sheet with Cash and Cash Equivalents of $127.8M as of December 31, 2021; Available Cash and Revenues Extend Cash Runway
65 Biggest Movers From Yesterday
Gainers
Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
78 Biggest Movers From Friday
Gainers
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering.
KemPharm Q2 EPS $0.18 Misses $0.22 Estimate, Sales $12.00M Miss $12.10M Estimate
KemPharm (NASDAQ:KMPH) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.22 by 18.18 percent. This is a 1700 percent increase over earnings of $0.01 per share from the same
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell
• Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.